Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States

Kathryn Kolibaba, MD, Jie Zhou, PhD, Scott Justin Keating, MS, Jamyia Clark, PhD MPH, John Brokars, MS, Arianna Kee, Ronda Copher, PhD, Brian Stwalley, PharmD BCGP, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141086

Published: 2020

Journal Articles

Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma

Blood (2014) 124 (21): 4701.

https://doi.org/10.1182/blood.V124.21.4701.4701

Published: 2014

Journal Articles

Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy

Rita Tohme, BS, Ronan Le Moigne, PhD, Bartlomiej P Przychodzen, Yingchun Han, MD, Mark Rolfe, PhD, Hetty E. Carraway, MD, Stevan Djakovic, PhD, Dan Anderson, PhD, David Wustrow, PhD, Han-Jie Zhou, PhD, Steve Wong, Kevin R. Kelly, MD, Yogen Saunthararajah, MD, Anjali S. Advani, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Steffan T. Nawrocki, PhD, Jennifer S. Carew, PhD

Blood (2014) 124 (21): 3766.

https://doi.org/10.1182/blood.V124.21.3766.3766

Published: 2014

Journal Articles

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Tony Muchamuel, Shirin Kapur, PhD, Christopher J Kirk, Ph.D, Jing Jiang, M.D., Susan Lee, Mark K Bennett, PhD, Evan Lewis, Jinfu Yang, Mouhannad Jumaa, Eileen Ring, Pasit Phiasivongsa, Han-Jie Zhou, PhD, Zhengping Wang

Blood (2009) 114 (22): 4910.

https://doi.org/10.1182/blood.V114.22.4910.4910

Published: 2009

Journal Articles

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Tony Muchamuel, Monette Aujay, Mark K Bennett, PhD, Maya Dajee, Susan Demo, PhD, Christopher J Kirk, Ph.D, Ying Fang, Jing Jiang, M.D., Evan Lewis, Yan Lu, Guy Laidig, Francesco Parlati, PhD, Jamie Shields, Congcong m Sun, Jinfu Yang, Han-Jie Zhou, PhD

Blood (2008) 112 (11): 3671.

https://doi.org/10.1182/blood.V112.11.3671.3671

Published: 2008

NARROW

A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States

Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma

Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Email alerts

ASH Publications

American Society of Hematology

A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States

Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma

Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only